Understand the source comparison
Peptides for Chronic Pain Research Compared: Mechanism Comparison
BPC-157 VEGF upregulation → angiogenesis and tissue repair Tendons, ligaments, joints, gastric mucosa VEGFR-2 expression, collagen organization, inflammatory cell count Phase II human trials (limited), extensive preclinical data in multiple species Strongest e
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- VEGF upregulation → angiogenesis and tissue repair
- Tendons, ligaments, joints, gastric mucosa
- VEGFR-2 expression, collagen organization, inflammatory cell count
- Phase II human trials (limited), extensive preclinical data in multiple species
- Strongest evidence for structural chronic pain (tendinopathy, OA). Mechanism directly addresses tissue hypoxia perpetuating inflammation.
- TB-500
- Actin polymerization → cellular mobility and tissue elasticity restoration
- Muscle, fascia, connective tissue
- Actin filament density, range-of-motion metrics, nociceptive threshold
- Predominantly preclinical (rodent and equine models)
- Best-suited for mobility-limited chronic pain where tissue stiffness drives mechanical pain. Human data lacking.
- KPV
- NF-kappaB inhibition → reduced inflammatory cytokine transcription
- Systemic (crosses BBB), effective in neural and epithelial tissue
- IL-6, TNF-alpha, IL-1beta, NF-kappaB nuclear translocation
- Phase I safety data, preclinical efficacy in IBD and neuropathic pain models
- Targeted application in cytokine-driven chronic pain. Does not address structural pathology. Purely biochemical modulation.